Three case reports from Iceland spurred the review; two of the cases involved Ozempic
No evidence seen for link between childhood stimulant treatment and substance use during adolescence and young adulthood
For first three approved indications, second and third indication approvals less likely to have high value rating
No impact on receipt of opioid or nonopioid pain treatment seen among patients with chronic noncancer pain
Strongest demographic predictor for discharge initiation of medications for alcohol use disorder was younger age
No significant difference in verified seven-day abstinence seen by treatment group among Black adults who smoke daily
Few offer other evidence-based treatments
Likelihood of not taking medication as prescribed due to cost increased for women versus men and for those with disabilities
Ketamine noninferior in terms of response to treatment; ECT linked to decrease in memory recall after treatment
Extended-release injection available in lower doses to be administered in health care settings by health care providers